DelveInsight’s Metastatic Castration-Resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Metastatic Castration-Resistant Prostate Cancer Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Metastatic Castration-Resistant Prostate Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and the current forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.
Metastatic Castration-Resistant Prostate Cancer: Overview
Prostate cancer is a type of malignancy that occurs in the prostate gland. It is one of the most common types of cancer found in men. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm. However, in 6-10% of cases, cancer has spread to parts of the body farther from the prostate, such as the lungs, liver, or bones, and is known as distant or metastatic prostate cancer.
Get access to a free copy of our latest sample report @ https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-market
Some of the key facts of the Metastatic Castration-Resistant Prostate Cancer Market Report
- According to the analysis, it was found that prostate cancer is more prevalent in people of age between 65–74 years followed by 55–64 years and 75–84 years.
- Approximately 1 in 9 men in the US will be diagnosed with prostate cancer at some point in their lives.
- The total prevalent cases of prostate cancer in the 7MM were observed to be 6,742,385 cases in 2017 which is expected to grow during the study period (2017–2030). In total prevalent cases of the 7MM; the US accounted for the highest number of cases which were 3,170,339 cases in 2017.
Metastatic Castration-Resistant Prostate Cancer Market
The Metastatic Castration-Resistant Prostate Cancer market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of Metastatic Castration-Resistant Prostate Cancer in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Metastatic Castration-Resistant Prostate Cancer market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Metastatic Castration-Resistant Prostate Cancer market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Metastatic Castration-Resistant Prostate Cancer Treatment Market
The treatment paradigm of mCRPC, is full of competition as many of the approved therapies are already present in the market and many of the therapies are present in the pipeline for fulfilling the unmet needs in mCRPC treatment.
Metastatic Castration-Resistant Prostate Cancer Market Insights
CRPC is defined by disease progression despite androgen depletion therapy (ADT) and may present as either a continuous rise in serum prostate-specific antigen (PSA) levels, the progression of pre-existing disease, or the appearance of new metastases. CRPC were introduced with the realization that intracrine or paracrine androgen production plays is significant in the resistance of prostate cancer cells to testosterone suppression therapy.
Metastatic Castration-Resistant Prostate Cancer Epidemiology
The epidemiology section covers insights into the historical and current Metastatic Castration Resistant Prostate Cancer patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Metastatic Castration-Resistant Prostate Cancer Market Drugs & Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Castration-Resistant Prostate Cancer market or expected to get launched in the market during the study period. The analysis covers Metastatic Castration-Resistant Prostate Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Metastatic Castration-Resistant Prostate Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Metastatic Castration-Resistant Prostate Cancer Emerging Therapies
The dynamics of the mCRPC market are anticipated to change in the coming years owing to the rise in the number of companies taking interest in the development of specific drugs for mCRPC along with increasing awareness and penetration of already approved prostate cancer drugs in mCRPC. Key players, such as AstraZeneca, Bristol-Myers Squibb, Janssen Research & Development, Hinova Pharmaceuticals, Hoffmann-La Roche, Pfizer, Astellas Pharma, Clovis Oncology, and others are involved in developing drugs for CRPC.
- Bayer Health Care
- Astellas Pharma
- Janssen Pharmaceutical
- Clovis Oncology, and Others
- Rubraca (Rucaparib)
- Lynparza (Olaparib)
- Jevtana (Cabazitaxel)
- Erleada (apalutamide)
- Xtandi (Enzalutamide)
- Xofigo (radium Ra 223 dichloride), and others
Metastatic Castration-Resistant Prostate Cancer Market Drivers
- Rising Geriatric Population and High Prevalence Rate
- The surge in Awareness Regarding the Treatment
- Increase in Demand for mCRPC Treatment Products
Metastatic Castration-Resistant Prostate Cancer Market Barriers
- Cost Constraints
- The Complex issue of Companion Diagnostics
- Entry Barrier
Table of content
- Key Insights
- Executive Summary
- Competitive Intelligence Analysis
- Market Overview at a Glance
- Disease Background and Overview
- Patient Journey
- Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Unmet Needs
- Key Endpoints of Metastatic Castration-Resistant Prostate Cancer Treatment
- Marketed Products
- Emerging Therapies
- Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview
- KOL Views
- Market Drivers
- Market Barriers
- DelveInsight Capabilities
- About DelveInsight
Consult with our Business Expert @ https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-market
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight
Contact Person: Yash
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States